Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP814303.RA_8eokmt0LR0ql4UDr2C1yn7b0kdU6wS7pmxZGCd4oLA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP814303.RA_8eokmt0LR0ql4UDr2C1yn7b0kdU6wS7pmxZGCd4oLA130_assertion type Assertion NP814303.RA_8eokmt0LR0ql4UDr2C1yn7b0kdU6wS7pmxZGCd4oLA130_head.
- NP814303.RA_8eokmt0LR0ql4UDr2C1yn7b0kdU6wS7pmxZGCd4oLA130_assertion description "[Our studies suggest that new strategies targeting erbB3 or Survivin may enhance the efficacy of chemotherapeutic agents against erbB2-overexpressing breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP814303.RA_8eokmt0LR0ql4UDr2C1yn7b0kdU6wS7pmxZGCd4oLA130_provenance.
- NP814303.RA_8eokmt0LR0ql4UDr2C1yn7b0kdU6wS7pmxZGCd4oLA130_assertion evidence source_evidence_literature NP814303.RA_8eokmt0LR0ql4UDr2C1yn7b0kdU6wS7pmxZGCd4oLA130_provenance.
- NP814303.RA_8eokmt0LR0ql4UDr2C1yn7b0kdU6wS7pmxZGCd4oLA130_assertion SIO_000772 20498641 NP814303.RA_8eokmt0LR0ql4UDr2C1yn7b0kdU6wS7pmxZGCd4oLA130_provenance.
- NP814303.RA_8eokmt0LR0ql4UDr2C1yn7b0kdU6wS7pmxZGCd4oLA130_assertion wasDerivedFrom befree-2016 NP814303.RA_8eokmt0LR0ql4UDr2C1yn7b0kdU6wS7pmxZGCd4oLA130_provenance.
- NP814303.RA_8eokmt0LR0ql4UDr2C1yn7b0kdU6wS7pmxZGCd4oLA130_assertion wasGeneratedBy ECO_0000203 NP814303.RA_8eokmt0LR0ql4UDr2C1yn7b0kdU6wS7pmxZGCd4oLA130_provenance.